Iovance Biotherapeutics, Inc. (IOVA) · Nov 5, 2026 · Earnings

Iovance earnings beat as Amtagvi sales accelerate and pipeline expands

Beat — Revenue $121.5M vs ~$115.5M consensus; EPS -$0.05 vs ~-$0.08 consensus

Iovance earnings showed a revenue beat and sharply narrower losses, while Amtagvi demand and new lung-cancer programs strengthen the commercial-to-pipeline story.

Iovance is transitioning from a single-product launch into a commercial TIL platform: Amtagvi is gaining treatment-center reach and demand while the company builds registrational programs in lung cancer, sarcoma, and frontline melanoma.

Commercial execution came in ahead of the standing bar. Third-quarter revenue rose to $121.5 million from $67.5 million a year earlier, above the published consensus of roughly $115.5 million; the company also reported a $0.05 per-share loss versus an expected loss of about $0.08. The filing attributes the record quarter to continued U.S. Amtagvi demand and says more than 1,000 patients have now been commercially treated.

Q3 2026Q3 2025Consensus
Revenue (Financial Highlights)$121.5M (+80.1%)$67.5M~$115.5M
Net loss per share (Income Statement)$(0.05)$(0.25)~$(0.08)
Operating loss (Income Statement)$(24.0)M$(94.9)M
Cash, investments and restricted cash (Balance Sheet)$382.3M$303.0M

The quality of the quarter improved, not just the top line. Gross profit was approximately $73.4 million, implying a roughly 60.5% gross margin versus about 42.9% a year ago, while the operating loss narrowed materially as research spending fell and last year’s restructuring charge disappeared. That is meaningful evidence that the commercial model is scaling, although Iovance remains loss-making and weighted average shares rose to 455.9 million from 364.0 million, reflecting substantial dilution.

The outlook was reaffirmed rather than upgraded. Iovance remains on track for $410 million to $420 million of 2026 revenue, but that range had already been raised on September 29, 2026 from $350 million to $370 million, so the current confirmation is more execution proof than a fresh guidance catalyst.

The pipeline adds strategic upside, but most of it is still clinical rather than commercial. The filing reports a 24.6% response rate in 69 non-small-cell lung-cancer patients and a 59.1% response rate in a biomarker-selected subgroup, supporting enrollment of POSITILITY and a planned 2027 supplemental application. It also reports a 55.6% confirmed response rate in nine sarcoma patients, but these are small, ongoing datasets and still require regulatory validation. 〔0〕 〔1〕 〔2〕

Bottom line: This is a modestly better-than-expected quarter that strengthens the commercial launch story and gives the broader pipeline more credibility. It matters, but it advances an existing trajectory rather than rewriting Iovance’s story overnight.

What to watch next

2027 sBLA submission for IOV-LUN-202

Original filing on SEC EDGAR

More Iovance Biotherapeutics, Inc. news

Iovance earnings beat as Amtagvi sales accelerate and pipeline expands | IOVA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.